We undertook a two-stage genome-wide association study (GWAS) of Alzheimer's disease (AD)
involving over 16,000 individuals, the most powerful AD GWAS to date. In stage 1 (3,941 …

We sought to identify new susceptibility loci for Alzheimer's disease through a staged
association study (GERAD+) and by testing suggestive loci reported by the Alzheimer's Disease …

In Alzheimer's disease (AD) Aβ accumulates because of imbalance between the production
of Aβ and its removal from the brain. There is increasing evidence that in most sporadic …

COVID-19 is primarily a respiratory disease but up to two thirds of hospitalised patients
show evidence of central nervous system (CNS) damage, predominantly ischaemic, in some …

Background Late Onset Alzheimer's disease (LOAD) is the leading cause of dementia.
Recent large genome-wide association studies (GWAS) identified the first strongly supported …

Cardiff casesa 41 121 36 203 193 (n= 198)(0.21)(0.61)(0.18)(0.51)(0.49) 2.43 Cardiff controls
12 38 27 62 92(1.4− 4.4)(n= 77)(0.16)(0.49)(0.35)(0.40)(0.60) London casesb 23 88 24 …

We investigated whether angiotensin II receptor blockers (ARBs) and angiotensin converting
enzyme inhibitors (ACE-Is) are more strongly associated with Alzheimer's disease (AD), …

There are no generally accepted protocols for post-mortem assessment in cases of
suspected vascular cognitive impairment. Neuropathologists from seven UK centres have …

Apolipoprotein E ε4 (APOE*4) is the only fully established susceptibility allele for Alzheimer's
disease. One of the most studied candidates is the insertion (I)/deletion (D) polymorphism (…

… Patrick G. Kehoe has almost 20 years of experience on Alzheimer’s disease, related
dementias, and mental health research. His initial interest in Alzheimer’s disease developed from …